Memorial Sloan Kettering Cancer Center is pleased to announce:

CONTEMPORARY MANAGEMENT OF COMPLEX SKIN CANCERS

November 4-5, 2016

Conference Location:
Memorial Sloan Kettering Cancer Center
Zuckerman Research Center
417 East 68th Street New York, NY 10065

www.mskcc.org/skin cancercourse
MSK Course Directors

Kishwer S. Nehal, MD
Director, Mohs Micrographic and Dermatologic Surgery

Bhuvanesh Singh, MD, PhD
Director, Laboratory of Epithelial Cancer Biology

MSK Faculty

Charlotte Ariyan, MD, PhD
Division of General Surgical Oncology

Christoper Barker, MD
Department of Radiation Oncology

Klaus Busam, MD
Department of Pathology

Jason Chen, MD, PhD
Hauppauge Dermatology Section

Daniel Coit, MD
Division of General Surgical Oncology

Karen Connolly, MD
Visiting Investigator

Sandra D’Angelo
Sarcoma Medical Oncology Service

Mark Dickson, MD
Sarcoma Medical Oncology Service

Jennifer Hay, PhD
Behavioral Sciences Service

Alan Ho, MD, PhD
Division of Solid Tumor Oncology

Travis Hollmann, MD, PhD
Department of Pathology

Erica Lee, MD
Dermatology Service

Brian Marr, MD
Department of Surgery

Babak Mehrara, MD
Plastic & Reconstructive Service

David Pfister
Head & Neck Oncology Service

Melissa Pulitzer, MD
Department of Pathology

Benjamin Roman, MD, MSHP
Department of Surgery

Anthony Rossi, MD
Dermatology Service

Alexander Shoushtari, MD
Medical Oncology

Steve Wang, MD
Dermatology Service

Guest Faculty

Scott McClean, MD
Assistant Professor, Otolaryngology
University of Michigan

Sue Yom, MD
Associate Professor, Department of Radiation Oncology

www.mskcc.org/skincancercourse
Course Overview

The purpose of this course is to provide the attendee with a multidisciplinary management approach for patients with skin cancer, including basal cell carcinoma, squamous cell carcinoma, merkel cell carcinoma, melanoma and other complex skin cancers. The topics will focus on advances in epidemiology, pathology and imaging, medical and surgical management and radiation therapy. Complex skin cancer cases will be presented and discussed in a tumor board style with a multidisciplinary panel of experts.

Educational Objectives

After Completion of this module, participants should be able to:

- Describe melanoma and non melanoma skin cancer incidence and behavior
- Define factors contributing to behavior and outcome of skin cancers
- Define characteristics of skin cancers that require aggressive treatment
- Understand benefits, limitations, and integration of different modalities used in the treatment of skin cancers
- Review novel approaches to optimize surgical treatment of skin cancers
- Assess role and variety of radiotherapeutic approaches to complex skin cancers
- Review role of biological therapy in the treatment of advanced skin cancers
- Examine the optimal approaches toward reconstruction of defects resulting from resection of skin cancers

Target Audience

Physicians and allied health professionals, who care for patients with skin cancer, including dermatologists, surgical and medical oncologists, otolaryngologists, ophthalmologists, general surgeons, plastic surgeons, pathologists and radiation oncologists.
Friday, November 4, 2016

7:30-8:00am  REGISTRATION AND BREAKFAST

8:00-8:15am  Introductory Remarks
Bhuvanesh Singh, MD, PhD and Kishwer S. Nehal, MD

8:15-8:35am  BASAL CELL CARCINOMA
MODERATOR: Kishwer S. Nehal, MD

8:15-8:35am  Treatment and Quality of life
Erica Lee, MD

8:35-8:50am  Surgical Pearls
Steve Wang, MD

8:50-9:05am  Optical Imaging of BCC, from Bench Top to Bedside
Jason Chen, MD, PhD

9:05-9:30am  Radiotherapy and Radiosensitization in the Curative Management of BCC
Sue Yom, MD

9:30-9:45am  Targeted Therapies for BCC
Alan Ho, MD, PhD

9:45-10:45am  TUMOR BOARD - BCC
All Faculty & Babak Mehrara, MD

9:45-10:45am  Multidisciplinary Challenging Cases – Audience Response Session; Q&A
Babak Mehrara, MD

10:45-11:00am  BREAK

11:00-11:30am  EYELID TUMORS & OTHER SKIN CANCERS
MODERATOR: Brian Marr, MD

11:00-11:30am  Sebaceous Carcinoma of the Eyelids & Eyelid Reconstruction
Brian Marr, MD

11:30-11:50am  Dermatofibrosarcoma Protuberans: Surgical Therapy
Karen Connolly, MD

11:50-12:15pm  Dermatofibrosarcoma Protuberans: Medical Therapy
Mark Dickson, MD

12:15-12:30pm  Q&A

12:30-1:30pm  LUNCH
Friday, November 4, 2016

**SQUAMOUS CELL CARCINOMA**
**MODERATOR:** Bhuvanesh Singh, MD, PhD

1:30-1:50pm  
**AJCC Staging/High Risk SCC**  
Benjamin Roman, MD, MSHP

1:50-2:05pm  
**Pathology**  
Travis Hollmann, MD, PhD

2:05-2:30pm  
**Nodal Management**  
Scott McClean, MD

2:30-2:55pm  
**Treatment Selection for Radiotherapy & Systemic Intensification in SCC**  
Sue Yom, MD

2:55-3:15pm  
**Systemic Therapy for SCC: Past Experience, Future Directions**  
David Pfister, MD

**TUMOR BOARD – SCC**
**All Faculty**

3:15-4:15pm  
**Multidisciplinary Challenging Cases – Audience Response Session; Q&A**
Saturday, November 5, 2016

8:00-8:30am BREAKFAST

MERKEL CELL CARCINOMA
MODERATOR: Christopher Barker, MD

8:30-8:50am Surgical Management
Scott McLean, MD

8:50-9:00am Pathology
Melissa Pulitzer, MD

9:00-9:15am Radiation Therapy
Christopher Barker, MD

9:15-9:30am Systemic Treatment Options for Metastatic Merkel Cell Carcinoma
Sandra D’Angelo, MD

TUMOR BOARD – MCC
All Faculty

9:30-10:30am Multidisciplinary Challenging Cases – Audience Response Session; Q&A

10:30-10:45am BREAK

LENTIGO MALIGNA MELANOMA
MODERATOR: Klaus Busam, MD

10:45-11:00am Surgical Management
Kishwer S. Nehal, MD

11:00-11:15am Pathology
Klaus Busam, MD

11:15-11:30pm Imiquimod / Confocal Imaging
Anthony Rossi, MD

11:30-11:45pm Radiation Therapy for Lentigo Maligna
Christopher Barker, MD

11:45-12:30pm Tumor Board Case Discussion – Audience Response Session; Q&A

12:30-1:30am LUNCH
Saturday, November 5, 2016

MELANOMA
MODERATOR: Charlotte Ariyan, MD PhD

1:30-1:50pm  Using Behavioral Science to Identify Novel Opportunities for Melanoma Prevention
Jennifer L. Hay, PhD

1:50-2:10pm  Update on Genomic Profiling of Primary Melanoma
Daniel Coit, MD

2:10-2:30pm  Changing Indications for Lymph Node Dissection
Charlotte Ariyan, MD, PhD

2:30-2:50pm  Updates on Adjuvant Treatment for Melanoma
Alexander Shoushtari, MD

2:50-3:00pm  Sunscreen
Steve Wang, MD

MELANOMA TUMOR BOARD
All Faculty

3:00-4:00pm  Multidisciplinary Challenging Cases – Audience Response Session; Q&A

“As a previous lecturer on skin cancers and facial dermatology, I found this course to be an excellent and superior sophisticated course. The quality of the presenters and the agenda was excellent.” - 2015 Course Participant
Registration

REGISTRATION FEES

<table>
<thead>
<tr>
<th></th>
<th>EARLY Before 9/9/16</th>
<th>GENERAL After 9/9/16</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDs, PhDs and DOs</td>
<td>$400</td>
<td>$450</td>
</tr>
<tr>
<td>MSK Alliance and MSK Alumni</td>
<td>$280</td>
<td>$315</td>
</tr>
<tr>
<td>Fellows, Resident, RNs and PAs</td>
<td>$75</td>
<td>$150</td>
</tr>
<tr>
<td>Industry Members*</td>
<td>$787.50</td>
<td>$787.50</td>
</tr>
</tbody>
</table>

*Industry Members: Registration is for educational purposes only. Marketing, sales, and promotion of products and services are prohibited at CME activities.

Register online at:
www.mskcc.org/skincancercourse

Registration includes continental breakfast, lunch, and refreshment breaks. Please contact us at least one week prior to the course if you have any special dietary needs.

Registration is complimentary for MSK staff who wish to attend this course. However, you must register online by visiting the Continuing Medical Education page on OneMSK.

CONTACT
Continuing Medical Education
Memorial Sloan Kettering Cancer Center
633 Third Avenue, 12th Floor New York, New York 10017
cme@mskcc.org

COURSE DESIGN
This course includes short didactic lectures intermixed with multidisciplinary tumor board cases.

EVALUATION
A course evaluation survey sent out electronically will provide attendees with the opportunity to review the sessions and the speakers and to identify future educational needs.

ACCREDITATION STATEMENT
MSK is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA CREDIT DESIGNATION STATEMENT
MSK designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. The AMA has determined that physicians not licensed in the United States but who participate in this CME activity are eligible for 13.0 AMA PRA Category 1 Credits™.

ACCOMMODATIONS
For information on hotels in the area of MSKCC with discounted rates, please visit: www.mskcc.org/accommodations.

FACULTY DISCLOSURE
It is the policy of MSK to make every effort to insure balance, independence, objectivity, and scientific rigor in all continuing medical education activities which it sponsors as an ACCME accredited provider. In accordance with ACCME guidelines and standards, all faculty participating in an activity sponsored by MSK are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services which are discussed by the faculty members in an educational presentation. As required by the ACCME, when an unlabeled use of a commercial product or an investigational use not yet approved for any purpose is discussed during an educational activity, MSK requires the speaker to disclose that the product is not labeled for the use under discussion or that the product is still investigational.

OUTCOMES MEASUREMENT SURVEY
Six months after the end of the course an Outcomes Measurement Survey will be sent to all participants to help us determine what positive impacts have been made on participant practice as a result of the course.